Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection

European Journal of Immunology

Volumn 44, Issue 10, 2014, Pages 2925-2937

  Dugast, Anne Sophie ^a   Stamatatos, Leonidas ^b,c   Tonelli, Andrew ^a   Suscovich, Todd J ^a   Licht, Anna F ^a   Mikell, Iliyana ^b,c   Ackerman, Margaret E ^d   Streeck, Hendrik ^e   Klasse, P J ^f   Moore, John P ^f   Alter, Galit ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d DARTMOUTH COLLEGE   (United States)

^e Weill Cornell Medical College ^*  (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

ADCC; Antibodies; HIV; IgG3

Indexed keywords

FC RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G3 ANTIBODY; NEUTRALIZING ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; VIRUS ANTIBODY;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MOLECULAR EVOLUTION; PRIORITY JOURNAL; VIRUS INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MIDDLE AGED;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; MIDDLE AGED;

EID: 84925236503     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201344305     Document Type: Article

References (57)

1. Tomaras, G. D., Yates, N. L., Liu, P., Qin, L., Fouda, G. G., Chavez, L. L., Decamp, A. C. et al., Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 2008. 82: 12449-12463.
2. Richman, D. D., Wrin, T., Little, S. J. and Petropoulos, C. J., Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 2003. 100: 4144-4149.
3. Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F. et al., Antibody neutralization and escape by HIV-1. Nature 2003. 422: 307-312.
4. Doria-Rose, N. A., Klein, R. M., Manion, M. M., O'Dell, S., Phogat, A., Chakrabarti, B., Hallahan, C. W. et al., Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 2009. 83: 188-199.
5. Sather, D. N., Armann, J., Ching, L. K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X. et al., Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 2009. 83: 757-769.
6. Mikell, I., Sather, D. N., Kalams, S. A., Altfeld, M., Alter, G. and Stamatatos, L., Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011. 7: e1001251.
7. Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J. P., Wang, S. K. et al., Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011. 477: 466-470.
8. Nimmerjahn, F. and Ravetch, J. V., Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008. 8: 34-47.
9. Alter, G., Teigen, N., Davis, B. T., Addo, M. M., Suscovich, T. J., Waring, M. T., Streeck, H. et al., Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 2005. 106: 3366-3369.
10. Koup, R. A., Sullivan, J. L., Levine, P. H., Brewster, F., Mahr, A., Mazzara, G., McKenzie, S. et al., Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J. Virol. 1989. 63: 584-590.
11. Tyler, D. S., Stanley, S. D., Nastala, C. A., Austin, A. A., Bartlett, J. A., Stine, K. C., Lyerly, H. K. et al., Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J. Immunol. 1990. 144: 3375-3384.
12. Lambotte, O., Ferrari, G., Moog, C., Yates, N. L., Liao, H. X., Parks, R. J., Hicks, C. B. et al., Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009. 23: 897-906.
13. Ljunggren, K., Karlson, A., Fenyo, E. M. and Jondal, M., Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection. Clin. Exp. Immunol. 1989. 75: 184-189.
14. Ahmad, A., Morisset, R., Thomas, R. and Menezes, J., Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 1994. 7: 428-437.
15. Forthal, D. N., Landucci, G. and Daar, E. S., Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 2001. 75: 6953-6961.
16. Baum, L. L., Cassutt, K. J., Knigge, K., Khattri, R., Margolick, J., Rinaldo, C., Kleeberger, C. A. et al., HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 1996. 157: 2168-2173.
17. Forthal, D. N., Landucci, G., Haubrich, R., Keenan, B., Kuppermann, B. D., Tilles, J. G. and Kaplan, J., Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J. Infect Dis. 1999. 180: 1338-1341.
18. Chung, A. W., Navis, M., Isitman, G., Centre, R., Finlayson, R., Bloch, M., Gelgor, L. et al., Activation of NK cells by ADCC responses during early HIV infection. Viral. Immunol. 2011. 24: 171-175.
19. Forthal, D. N., Landucci, G. and Keenan, B., Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res. Hum. Retroviruses 2001. 17: 553-561.
20. Mellors, J. W., Rinaldo, C. R., Jr., Gupta, P., White, R. M., Todd, J. A. and Kingsley, L. A., Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996. 272: 1167-1170.
21. Simek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., Lehrman, J. K. et al., Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 2009. 83: 7337-7348.
22. Giorgi, J. V., Liu, Z., Hultin, L. E., Cumberland, W. G., Hennessey, K. and Detels, R., Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 1993. 6: 904-912.
23. Wherry, E. J., Ha, S. J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S. et al., Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007. 27: 670-684.
24. Titanji, K., Chiodi, F., Bellocco, R., Schepis, D., Osorio, L., Tassandin, C., Tambussi, G. et al., Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 2005. 19: 1947-1955.
25. De Milito, A., Nilsson, A., Titanji, K., Thorstensson, R., Reizenstein, E., Narita, M., Grutzmeier, S. et al., Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 2004. 103: 2180-2186.
26. Morell, A., Terry, W. D. and Waldmann, T. A., Metabolic properties of IgG subclasses in man. J. Clin. Invest. 1970. 49: 673-680.
27. Yates, N. L., Lucas, J. T., Nolen, T. L., Vandergrift, N. A., Soderberg, K. A., Seaton, K. E., Denny, T. N. et al., Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS 2011. 25: 2089-2097.
28. Moore, P. L., Gray, E. S., Choge, I. A., Ranchobe, N., Mlisana, K., Abdool Karim, S. S., Williamson, C. et al., The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J. Virol. 2008. 82: 1860-1869.
29. Dhillon, A. K., Donners, H., Pantophlet, R., Johnson, W. E., Decker, J. M., Shaw, G. M., Lee, F. H. et al., Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 2007. 81: 6548-6562.
30. Scheid, J. F., Mouquet, H., Feldhahn, N., Seaman, M. S., Velinzon, K., Pietzsch, J., Ott, R. G. et al., Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009. 458: 636-640.
31. Nandi, A., Lavine, C. L., Wang, P., Lipchina, I., Goepfert, P. A., Shaw, G. M., Tomaras, G. D. et al., Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 2010. 396: 339-348.
32. Kohl, S., Role of antibody-dependent cellular cytotoxicity in defense against herpes simplex virus infections. Rev. Infect. Dis. 1991. 13: 108-114.
33. Hashimoto, G., Wright, P. F. and Karzon, D. T., Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J. Infect. Dis. 1983. 148: 785-794.
34. Biburger, M., Aschermann, S., Schwab, I., Lux, A., Albert, H., Danzer, H., Woigk, M. et al., Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 2011. 35: 932-944.
35. Kramski, M., Parsons, M. S., Stratov, I. and Kent, S. J., HIV-specific antibody immunity mediated through NK cells and monocytes. Curr. HIV Res. 2013. 11: 388-406.
36. Kramski, M., Schorcht, A., Johnston, A. P., Lichtfuss, G. F., Jegaskanda, S., De Rose, R., Stratov, I. et al., Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. J. Immunol. Methods 2012. 384: 51-61.
37. Ahmad, R., Sindhu, S. T., Toma, E., Morisset, R., Vincelette, J., Menezes, J. and Ahmad, A., Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 2001. 21: 227-233.
38. Xiao, P., Zhao, J., Patterson, L. J., Brocca-Cofano, E., Venzon, D., Kozlowski, P. A., Hidajat, R. et al., Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 2010. 84: 7161-7173.
39. Asmal, M., Sun, Y., Lane, S., Yeh, W., Schmidt, S. D., Mascola, J. R. and Letvin, N. L., Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses. J. Virol. 2011. 85: 5465-5475.
40. Doria-Rose, N. A. and Connors, M., Antibody-secreting B cells in HIV infection. Curr. Opin. HIV AIDS 2009. 4: 426-430.
41. Piantadosi, A., Panteleeff, D., Blish, C. A., Baeten, J. M., Jaoko, W., McClelland, R. S. and Overbaugh, J., Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 2009. 83: 10269-10274.
42. Brockman, M. A., Kwon, D. S., Tighe, D. P., Pavlik, D. F., Rosato, P. C., Sela, J., Porichis, F. et al., IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood 2009. 114: 346-356.
43. Tomaras, G. D. and Haynes, B. F., HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr. Opin. HIV AIDS 2009. 4: 373-379.
44. Nimmerjahn, F. and Ravetch, J. V., Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005. 310: 1510-1512.
45. Jefferis, R., Antibody therapeutics: isotype and glycoform selection. Expert. Opin. Biol. Ther. 2007. 7: 1401-1413.
46. Lux, A. and Nimmerjahn, F., Impact of differential glycosylation on IgG activity. Adv. Exp. Med. Biol. 2011. 780: 113-124.
47. Schroeder, H. W., Jr. and Cavacini, L., Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 2010. 125: S41-S52.
48. Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S. and Daeron, M., Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009. 113: 3716-3725.
49. Rozsnyay, Z., Sarmay, G., Walker, M., Maslanka, K., Valasek, Z., Jefferis, R. and Gergely, J., Distinctive role of IgG1 and IgG3 isotypes in Fc gamma R-mediated functions. Immunology 1989. 66: 491-498.
50. Jefferis, R., Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 2012. 526: 159-166.
51. Ravetch, J. V., Siebenlist, U., Korsmeyer, S., Waldmann, T. and Leder, P., Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes. Cell 1981. 27: 583-591.
52. Banerjee, K., Klasse, P. J., Sanders, R. W., Pereyra, F., Michael, E., Lu, M., Walker, B. D. et al., IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res. Hum. Retroviruses 2010. 26: 445-458.
53. Lane, H. C., Masur, H., Edgar, L. C., Whalen, G., Rook, A. H. and Fauci, A. S., Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 1983. 309: 453-458.
54. Alter, G., Malenfant, J. M. and Altfeld, M., CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 2004. 294: 15-22.
55. Moore, J. P. and Jarrett, R. F., Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1. Aids Res. Hum. Retroviruses 1988. 4: 369-379.
56. Brown, E. P., Licht, A. F., Dugast, A. S., Choi, I., Bailey-Kellogg, C., Alter, G. and Ackerman, M. E., High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J. Immunol. Methods 2012. 386: 117-123.
57. Derby, N. R., Gray, S., Wayner, E., Campogan, D., Vlahogiannis, G., Kraft, Z., Barnett, S. W. et al., Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens. Virology 2007. 366: 433-445.